Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) shares rose as much as 10% in early trading after the company said it expects to report revenue of £1.7 million for 2025, ahead of earlier guidance.
The Surrey-based healthcare group, known for its erectile dysfunction treatment Eroxon, ended the year with £3.4 million in cash following a £2.75 million fundraise in November.
Futura anticipates a tax credit refund of approximately £300,000 and expects to receive a milestone payment of US$2.5 million from healthcare multinational Haleon in the first half of 2026, subject to the grant of a US patent for Eroxon.
The company said its combined cash resources and expected inflows would provide a financial runway through to December 2026.
A strategic review of the business is underway and is expected to conclude in the first quarter of 2026. Outcomes will be published with full-year results in mid-April.
Eroxon is a clinically tested, non-prescription topical gel available in several European markets. It is Futura’s lead commercial asset and a key focus of its licensing strategy.
After an energetic initial burst, the stock settled at 1.36p, up 3%.